Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy ADT in High Risk Prostate Cancer with Initial Phase I NADIR Randomized Phase II Trial of Niraparib with Standard Combination Androgen Deprivation Therapy ADT and Radiotherapy in High Risk Prostate Cancer with Initial Phase I
A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study ICON study number: 0798/0661
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician?s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01
Study Type: Treatment
Phase: III
NCTID: NCT06120491
Principal Investigator:
Elizabeth Wulff-Burchfield
Pilot Trial of Ultra-Hypofractionated Radiation in Early Prostate Cancer
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT03486821
Principal Investigator:
Xinglei Shen
Multiparametric MRI mpMRI for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
The Role of Androgen Deprivation Therapy In CArdiovascular Disease ? A Longitudinal Prostate Cancer Study RADICAL PC1 and A RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients RADICAL PC2
A Phase II Study of M1774 in Refractory SPOP-Mutant Prostate Cancer
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy INNOVATE INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
A Phase III, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator?s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor ARPI, in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC - rechARge
Study Type: Treatment
Phase: III
NCTID: NCT06764485
Principal Investigator:
Haoran Li